|
10th Annual Conference on the Science of Dissemination and Implementation
|
Meeting/ Workshop
|
AHRQ
|
NHLBI, NCCIH, NCI, NIAAA, NIAID, NIDA, NIDDK, NIMH, NINR
|
A forum for discussing the science of dissemination and implementation, the 10th annual conference aimed to grow the research base by bridging the gap between evidence, practice, and policy in health and medicine.
|
|
2016 NCI SBIR Workshop on Facilitating the Development of Molecularly Targeted Radiotherapy
|
Training Initiative
|
FDA
|
NCI
|
As part of its continued effort to support awardee companies'' journey to commercialization, NCI SBIR Development Center hosted a specialized workshop for awardee companies developing molecularly targeted radiotherapy. The Workshop on Facilitating the Development of Molecularly Targeted Radiotherapy (hereinafter TRT Workshop) brought together experts from the SBIR program, NCI Radiation Research program, Food and Drug Administration''s Center for Drug Evaluation and Research (FDA CDER), and Department of Energy''s Isotope program to introduce the regulatory and clinical processes relevant to workshop participants.
|
|
2018 Physical Activity Guidelines Advisory Committee Report
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
OD/DPCPSI/ODP, NCI
|
The 2018 Physical Activity Guidelines Advisory Committee submitted its Scientific Report to the Secretary of Health and Human Services in February 2018. The report summarizes the scientific evidence on physical activity and health and will be used by the government to develop the second edition of the Physical Activity Guidelines for Americans. The HHS ODPHP coordinates the overall effort for this activity and oversees the FACA. The NIH ODP coordinates NIH input on this effort.
|
|
A Pilot Study of Urinary Carcinogen Biomarkers in the Golestan Cohort Study
|
Research Initiative
|
CDC, FDA
|
NCI
|
A pilot study in the Golestan Cohort to compare exposure to different types of carcinogens (nicotine metabolites, polycyclic aromatic hydrocarbons [PAHs], tobacco-specific nitrosamines [TSNAs], and volatile organic compounds [VOCs]) and creatine in the urine of self-reported cigarette, chewing nass, water pipe, and opium users, and those who never use these products. The study will examine the stability of these markers over time by taking advantage of repeated samples that were collected from a subset of participants. Results from the pilot study will then be used to evaluate the potential of future studies and evaluate their design.
|
|
A Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews
|
Research Initiative
|
CDC
|
NCI
|
NCI and CDC are collaborating on a cross-sectional study of 83 airline pilots and 50 university faculty to assess the relation of stable chromosome translocations with cosmic radiation exposure.
|
|
A Working Group to Consider the Question of Federal Public Health and Medical Resource Allocation
|
Committee, Work group, Advisory group, or Task Force
|
OS
|
CC
|
THe NIH Clinical Center is participating in a working group to consider the question of federal public health and medical resource allocation. The group developed a framework for allocation of federal resources during scarcity after engaging with stakeholders in ethics, disaster preparedness, and emergency management.
|
|
A5349/TBTC S31 - Rifapentine - Containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-Label, Controlled Phase 3 Clinical Trial
|
Research Initiative
|
CDC
|
NIAID
|
The purpose of this research initiative is to provide scientific discovery to improve patient care and safety by reducing the duration of treatment for drug-susceptible pulmonary tuberculosis to 4 months by using new regimens, including high-dose rifapentine.
|
|
Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT)
|
Research Initiative
|
FDA
|
NIDA
|
Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) is part of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration (FDA). The mission of the (ACTTION) is to identify, prioritize, sponsor, coordinate, and promote innovative activities with a special interest in optimizing clinical trials that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of public health.
|
|
Accelerating Medicines Partnership
|
Other
|
FDA
|
OD/OSP, NIA, NIAMS, NIDDK, NINDS
|
The Accelerating Medicines Partnership (AMP) is a public-private partnership, between NIH, FDA, 10 biopharmaceutical companies and multiple non-profit organizations, and managed by the Foundation for NIH (FNIH), to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets for therapeutics. The ultimate goal is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them. AMP was launched in February 2014, with projects in three disease areas (Alzheimer’s disease; type 2 diabetes; and autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus). Steering committees for each of the three disease areas, with representation from all partners, meet regularly to review ongoing progress and milestones. The steering committees are managed by FNIH under the direction of an AMP Executive Committee comprised of representatives from NIH, participating industry leaders, FDA, and non-profit organizations.
|
|
AccessGUDID
|
Resource Development
|
FDA
|
NLM
|
The Global Unique Device Identification Database (GUDID) contains key device identification information submitted to the FDA about medical devices that have Unique Device Identifiers (UDI). The National Library of Medicine (NLM), in collaboration with the FDA, has created the AccessGUDID portal to make device identification information in the GUDID available for everyone, including patients, caregivers, healthcare providers, hospitals, and industry.
|